Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
Adenoviridae
Animals
Drug Resistance, Neoplasm
Female
Immune Checkpoint Inhibitors
/ pharmacology
Interleukin-2
/ immunology
Melanoma, Experimental
/ pathology
Mice
Mice, Inbred C57BL
Oncolytic Virotherapy
/ methods
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Tumor Necrosis Factor-alpha
/ immunology
adenovirus
cancer immunotherapy
checkpoint inhibitor resistance
oncolytic virus
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
05
2021
accepted:
05
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted of adenoviruses engineered to express tumor necrosis factor alpha and interleukin-2 in the tumor microenvironment. To study virus efficacy in checkpoint-inhibitor resistant tumors, we developed an anti-PD-1 resistant melanoma model
Identifiants
pubmed: 34367166
doi: 10.3389/fimmu.2021.706517
pmc: PMC8343222
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Interleukin-2
0
Programmed Cell Death 1 Receptor
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
706517Informations de copyright
Copyright © 2021 Cervera-Carrascon, Quixabeira, Santos, Havunen, Milenova, Verhoeff, Heiniö, Zafar, Garcia-Vallejo, van Beusechem, de Gruijl, Kalervo, Sorsa, Kanerva and Hemminki.
Déclaration de conflit d'intérêts
AH is shareholder in Targovax ASA (Oslo, Norway) and in TILT Biotherapeutics Ltd. (Helsinki, Finland). AH, RH, SS, JS, and VC-C are employees of TILT Biotherapeutics Ltd. IM is employed by Orca Therapeutics, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2020 Jun 15;80(12):2575-2585
pubmed: 32107211
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Oncoimmunology. 2016 Dec 23;6(1):e1261779
pubmed: 28197389
Mol Ther. 2016 Aug;24(8):1435-43
pubmed: 27357626
JAMA Oncol. 2020 Mar 1;6(3):402-408
pubmed: 31971541
Hum Vaccin Immunother. 2015;11(7):1573-84
pubmed: 25996182
Nature. 2018 Oct;562(7725):20-21
pubmed: 30279600
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
PLoS One. 2015 Jun 24;10(6):e0131242
pubmed: 26107883
J Clin Invest. 2017 Mar 1;127(3):780-789
pubmed: 28248200
Mol Ther Oncolytics. 2020 Mar 19;17:47-60
pubmed: 32322662
Oncoimmunology. 2018 Oct 29;8(2):e1532763
pubmed: 30713786
Cancer Immunol Res. 2015 Aug;3(8):915-25
pubmed: 25977260
Oncoimmunology. 2018 Mar 26;7(7):e1445453
pubmed: 29900056
Hum Gene Ther. 2019 Jun;30(6):740-752
pubmed: 30672366
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991686
Expert Opin Biol Ther. 2019 May;19(5):443-455
pubmed: 30905206
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618658
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Eur J Cancer. 2019 Aug;117:14-31
pubmed: 31229946
Mol Ther Oncolytics. 2018 Nov 06;11:109-121
pubmed: 30569015
Gene Ther. 2005 Aug;12(15):1198-205
pubmed: 15800658
Gene Ther. 2009 Aug;16(8):1009-20
pubmed: 19440223
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Mol Ther. 2007 Apr;15(4):651-9
pubmed: 17299401
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Gene Ther. 2009 Dec;16(12):1441-51
pubmed: 19710704
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Cancer Discov. 2016 May;6(5):546-59
pubmed: 26928313
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
J Immunother Cancer. 2019 Dec 4;7(1):341
pubmed: 31801636
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Cancer Immunol Res. 2015 May;3(5):449-54
pubmed: 25691326
Oncoimmunology. 2018 Apr 9;7(5):e1412902
pubmed: 29721366
Front Cell Dev Biol. 2018 Apr 04;6:38
pubmed: 29670880
Oncoimmunology. 2018 May 7;7(8):e1457596
pubmed: 30221051
Nat Commun. 2021 May 20;12(1):2965
pubmed: 34017005
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
Eur J Immunol. 1988 Feb;18(2):313-6
pubmed: 3350037
Oncolytic Virother. 2018 Jul 31;7:65-77
pubmed: 30105219
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Oncoimmunology. 2020 Mar 12;9(1):1737369
pubmed: 32313720
Cells. 2020 Mar 26;9(4):
pubmed: 32225009
Front Oncol. 2019 Mar 29;9:195
pubmed: 30984621
Cancer J. 2017 Jan/Feb;23(1):10-22
pubmed: 28114250
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588
Cell. 2019 Jul 25;178(3):585-599.e15
pubmed: 31303383
Trends Cell Biol. 2020 Sep;30(9):695-704
pubmed: 32624246